 |
|
Comparative Efficiency of Prostate-Specific Antigen Screening Strategies for Prostate Cancer Detection
Kevin S. Ross, MPH;
H. Ballentine Carter, MD;
Jay D. Pearson, PhD;
Harry A. Guess, MD, PhD
JAMA. 2000;284:1399-1405.
Context Despite widespread use of serum prostate-specific antigen (PSA) testing to detect prostate cancer, the relative effectiveness of different PSA screening strategies is unknown.
Objective To compare prostate cancer mortality, PSA testing rates, and biopsy rates using various PSA screening strategies, including the standard strategy of annually testing men aged 50 through 75 years.
Design and Setting A Monte-Carlo simulation based on a Markov model was used to simulate the natural history of prostate cancer using different starting ages, testing intervals, and PSA thresholds for prostate biopsy. Age-specific PSA levels and prostate biopsy detection probabilities were determined from population data and surgical series.
Main Outcome Measures Numbers of prevented prostate cancer deaths, PSA tests, and prostate biopsies per 1000 men aged 40 through 80 years, compared among 7 different strategies vs no screening.
Results Compared with annual PSA testing beginning at age 50 years, the strategy of PSA testing at ages 40 and 45 years followed by biennial testing beginning at age 50 years was estimated to simultaneously reduce prostate cancer mortality and number of PSA tests and biopsies performed per 1000 men. Specifically, compared with no screening, the standard strategy prevents 3.2 deaths, with an additional 10,500 PSA tests and 600 prostate biopsies, while the earlier but less frequent strategy prevents 3.3 deaths, with an additional 7500 PSA tests and 450 prostate biopsies. Strategies that lowered the PSA threshold for prostate biopsy to below 4.0 ng/mL or strategies that used age-specific PSA levels were not more efficient than use of a PSA threshold of 4.0 ng/mL. These 2 findings remained true under all sensitivity analyses performed to test assumptions of the model.
Conclusion Recognizing that the efficacy of PSA screening is unproved, the standard strategy of annual PSA screening beginning at age 50 years appears to be less effective and more resource intensive compared with a strategy that begins earlier but screens biennially instead of annually.
Author Affiliations: Department of Epidemiology, University of North Carolina at Chapel Hill (Mr Ross and Dr Guess); Department of Urology, The Johns Hopkins University School of Medicine, James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Md (Drs Carter and Pearson); and Department of Epidemiology, Merck Research Laboratories, Blue Bell, Pa (Drs Pearson and Guess).
RELATED ARTICLE
September 20, 2000
JAMA. 2000;284(11):1451-1452.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Trends in Prostate-Specific Antigen Testing From 1995 Through 2004
Farwell et al.
Arch Intern Med 2007;167:2497-2502.
ABSTRACT
| FULL TEXT
Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial
Lane et al.
BMJ 2007;335:1139-1139.
ABSTRACT
| FULL TEXT
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
Carter et al.
JNCI J Natl Cancer Inst 2006;98:1521-1527.
ABSTRACT
| FULL TEXT
Viewpoint: limiting prostate cancer screening.
Hoffman
ANN INTERN MED 2006;144:438-440.
ABSTRACT
| FULL TEXT
Biomarkers for Cancer Diagnosis: Implications for Nutritional Research
Maruvada and Srivastava
J. Nutr. 2004;134:1640S-1645S.
ABSTRACT
| FULL TEXT
Second Round Results of the Finnish Population-Based Prostate Cancer Screening Trial
Makinen et al.
Clin. Cancer Res. 2004;10:2231-2236.
ABSTRACT
| FULL TEXT
Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
Harris and Lohr
ANN INTERN MED 2002;137:917-929.
ABSTRACT
| FULL TEXT
Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends
Etzioni et al.
JNCI J Natl Cancer Inst 2002;94:981-990.
ABSTRACT
| FULL TEXT
Pathologic Features of Prostate Cancer Found at Population-Based Screening With a Four-Year Interval
Hoedemaeker et al.
JNCI J Natl Cancer Inst 2001;93:1153-1158.
ABSTRACT
| FULL TEXT
Phases of Biomarker Development for Early Detection of Cancer
Pepe et al.
JNCI J Natl Cancer Inst 2001;93:1054-1061.
FULL TEXT
Prostate-Specific-Antigen Testing for Early Diagnosis of Prostate Cancer
Barry
NEJM 2001;344:1373-1377.
FULL TEXT
Earlier, Less Frequent PSA Sampling May Be Superior Strategy
JWatch Gastroenterology 2000;2000:14-14.
FULL TEXT
Earlier, Less Frequent PSA Sampling May Be Superior Strategy
Journal Watch Dermatology 2000;2000:14-14.
FULL TEXT
Earlier, Less Frequent PSA Sampling May Be Superior Strategy
JWatch General 2000;2000:3-3.
FULL TEXT
|
